CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. FIRST AMENDMENT TO...Material Transfer Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
This first amendment (“First Amendment”) is made effective as of April 3, 2020 (“Amendment Effective Date”) and shall serve to modify that certain Material Transfer Agreement dated March 23, 2020 (“Agreement”) by and between Bio-Rad Laboratories, Inc. (“Bio-Rad”) and Biodesix, Inc. (“Biodesix”).
ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATIONAsset Purchase Agreement and Plan of Reorganization • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
THIS ASSET PURCHASE AGREEMENT AND PLAN OF REORGANIZATION (the “Agreement”) is made and entered into as of June 30, 2018, by and between: BIODESIX, INC., a Delaware corporation (“Purchaser”); INTEGRATED DIAGNOSTICS, INC., a Delaware corporation (“Seller”); and the stockholders of Seller set forth on Exhibit A (each a “Stockholder”). Certain capitalized terms used in this Agreement are defined in Exhibit B.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. MATERIAL TRANSFER...Material Transfer Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
THIS MATERIAL TRANSFER AGREEMENT (“Agreement”), effective March 23, 2020 (“Effective Date”), is entered into between Biodesix, Inc., (hereinafter, “Biodesix”) having a place of business at 2970 Wilderness Place, Suite 100, Boulder, CO 80301, and BIO-RAD LABORATORIES, INC. (hereinafter “Bio-Rad”) having a place of business at 1000 Alfred Nobel Drive, Hercules CA 94547 (individually, a “Party”, and collectively, “Parties”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SECOND AMENDMENT TO...Testing Laboratory Services Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
This second amendment (“Second Amendment”) is made effective as of May 27, 2020 (“Amendment Effective Date”) and shall serve to modify that certain COVID-19 Testing Laboratory Services Agreement dated April 3, 2020 (“Agreement”) by and between Centura Health Corporation (“Hospital”) and Biodesix, Inc. (“Biodesix”).
PATENT ASSIGNMENTPatent Assignment • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
This Patent Assignment (“Assignment”) is made and entered into as of June 30, 2018 by and between Integrated Diagnostics, Inc., a corporation organized and existing under the laws of Delaware, having a place of business at 219 Terry Avenue North, Suite 100, Seattle, Washington 98109 USA (“Integrated Diagnostics”) and Biodesix, Inc., a corporation organized and existing under the laws of Delaware, having a place of business at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301 USA (“Biodesix”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. THIRD AMENDMENT TO...Testing Laboratory Services Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
This third amendment (“Third Amendment”) is made effective as of August 7, 2020 (“Amendment Effective Date”) and shall serve to modify that certain COVID-19 Testing Laboratory Services Agreement dated April 3, 2020 (“Agreement”) by and between Centura Health Corporation (“Hospital”) and Biodesix, Inc. (“Biodesix”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. MATERIAL TRANSFER...Material Transfer Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
THIS MATERIAL TRANSFER AGREEMENT (“Agreement”), effective this April 17, 2020 (“Effective Date”), is entered into between Biodesix, Inc., (hereinafter, “Recipient”) having a place of business at 2970 Wilderness Place, Suite 100, Boulder, CO 80301, and BIO-RAD LABORATORIES, INC. (hereinafter “Bio-Rad”) having a place of business at 1000 Alfred Nobel Drive, Hercules CA 94547 (individually, a “Party”, and collectively, “Parties”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. FIRST AMENDMENT TO...Testing Laboratory Services Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
This first amendment (“First Amendment”) is made effective as of April 23, 2020 (“Amendment Effective Date”) and shall serve to modify that certain COVID-19 Testing Laboratory Services Agreement dated April 3, 2020 (“Agreement”) by and between Centura Health Corporation (“Hospital”) and Biodesix, Inc. (“Biodesix”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.Industrial Lease Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.Price Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
Proposal and pricing set forth above is valid for thirty (30) days pending acceptance and counter-signature of this agreement. Term of this agreement is (36) thirty-six months from the Effective Date. Monthly kit volumes will be reviewed on a quarterly basis and pricing may be subject to increase for noncompliance.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. BIODESIX, INC....Investor Rights Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Colorado
THIS ELEVENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 10, 2018, by and among BIODESIX, INC., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. LIMITED CONSENT...Loan and Security Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • New York
This LIMITED CONSENT AGREEMENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Consent”) is made as of this 30th day of June, 2018, by and among BIODESIX, INC., a Delaware corporation (“Borrower”) and INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership in its capacity as Collateral Agent (“Collateral Agent”) for the Lenders and as a Lender (in such capacity, the “Required Lenders”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. CONTINGENT VALUE...Contingent Value Rights Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of February 22, 2016 (the “Effective Date”), is entered into by and among Biodesix, Inc., a Delaware corporation (the “Company”) and each of the holders set forth on Exhibit A hereto (each a “Holder”). Certain terms used herein are defined in Section 1.1 hereof.
ASSET PURCHASE AGREEMENT BY AND BETWEEN ONCIMMUNE LIMITED AND BIODESIX, INC. Dated as of June 27, 2019Asset Purchase Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of June 27, 2019 (the “Execution Date”), is by and between Oncimmune Limited, a private limited company incorporated under the laws of England and Wales (“Seller”), and Biodesix, Inc., a Delaware corporation (“Buyer”). Each of Seller and Buyer are sometimes referred to herein as a “Party” or collectively as the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories
David Brunel and Biodesix, Inc. (“Company”) (together, the “Parties”) hereby enter into this Consulting Agreement (“Agreement”) dated and effective as of September 19, 2020 (the “Effective Date”) and agree as follows:
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. COVID-19 TESTING...Testing Laboratory Services Agreement • October 2nd, 2020 • Biodesix Inc • Services-medical laboratories • Colorado
This COVID-19 TESTING LABORATORY SERVICES AGREEMENT (this “Agreement”) is made as of April 3, 2020 by and between Biodesix, Inc. (“Biodesix”), a Delaware corporation with its usual place of business at 2790 Wilderness Place, Boulder, CO 80301, and Centura Health Corporation (“Hospital”), a nonprofit corporation with its usual place of business at located at 9100 E. Mineral Circle, Centennial, CO 80112.
